nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—ABCB1—peripheral nervous system neoplasm	0.356	1	CbGaD
Lenalidomide—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0501	0.184	CbGbCtD
Lenalidomide—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0493	0.181	CbGbCtD
Lenalidomide—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0415	0.152	CbGbCtD
Lenalidomide—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0415	0.152	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0288	0.106	CbGbCtD
Lenalidomide—TNFSF11—skull—peripheral nervous system neoplasm	0.0192	0.303	CbGeAlD
Lenalidomide—TNFSF11—forelimb—peripheral nervous system neoplasm	0.0185	0.292	CbGeAlD
Lenalidomide—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0177	0.065	CbGbCtD
Lenalidomide—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0165	0.0606	CbGbCtD
Lenalidomide—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0162	0.0595	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0111	0.0406	CbGbCtD
Lenalidomide—TNFSF11—tongue—peripheral nervous system neoplasm	0.00989	0.156	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—ALK—peripheral nervous system neoplasm	0.00851	0.261	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—IFNB1—peripheral nervous system neoplasm	0.00681	0.209	CbGpPWpGaD
Lenalidomide—CDH5—trigeminal ganglion—peripheral nervous system neoplasm	0.00369	0.0582	CbGeAlD
Lenalidomide—CDH5—parotid gland—peripheral nervous system neoplasm	0.00348	0.0549	CbGeAlD
Lenalidomide—CRBN—trigeminal ganglion—peripheral nervous system neoplasm	0.00235	0.037	CbGeAlD
Lenalidomide—CRBN—parotid gland—peripheral nervous system neoplasm	0.00221	0.0349	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—HGF—peripheral nervous system neoplasm	0.00218	0.0671	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—PTPN11—peripheral nervous system neoplasm	0.00162	0.0498	CbGpPWpGaD
Lenalidomide—CDH5—cerebellum—peripheral nervous system neoplasm	0.00161	0.0254	CbGeAlD
Lenalidomide—Pomalidomide—ABCB1—peripheral nervous system neoplasm	0.00138	1	CrCbGaD
Lenalidomide—CRBN—cerebellum—peripheral nervous system neoplasm	0.00102	0.0161	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PTPN11—peripheral nervous system neoplasm	0.000914	0.0281	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—peripheral nervous system neoplasm	0.000907	0.0279	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT1—peripheral nervous system neoplasm	0.000722	0.0222	CbGpPWpGaD
Lenalidomide—PTGS2—trigeminal ganglion—peripheral nervous system neoplasm	0.000639	0.0101	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PTPN11—peripheral nervous system neoplasm	0.000636	0.0195	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000629	0.0193	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PTPN11—peripheral nervous system neoplasm	0.0006	0.0184	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000555	0.017	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—PTPN11—peripheral nervous system neoplasm	0.000544	0.0167	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000448	0.0138	CbGpPWpGaD
Lenalidomide—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000395	0.00623	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—peripheral nervous system neoplasm	0.000382	0.0117	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—peripheral nervous system neoplasm	0.000361	0.0111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—peripheral nervous system neoplasm	0.000355	0.0109	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	0.00028	0.00859	CbGpPWpGaD
Lenalidomide—PTGS2—cerebellum—peripheral nervous system neoplasm	0.000279	0.00439	CbGeAlD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD34—peripheral nervous system neoplasm	0.000277	0.00851	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	0.000264	0.00811	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	0.000247	0.00758	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.000233	0.00716	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000228	0.00699	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000218	0.00671	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000189	0.00582	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.000181	0.00556	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000173	0.0053	CbGpPWpGaD
Lenalidomide—ABCB1—cerebellum—peripheral nervous system neoplasm	0.000172	0.00272	CbGeAlD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.00016	0.00492	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000159	0.00489	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000134	0.00412	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.00012	0.00367	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000114	0.00351	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	0.000114	0.0035	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	0.000113	0.00347	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000102	0.00314	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000101	0.00311	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.75e-05	0.003	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	9.64e-05	0.00296	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	9.44e-05	0.0029	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	9.28e-05	0.00285	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.95e-05	0.00275	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	8.6e-05	0.00264	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	8.46e-05	0.0026	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	7.75e-05	0.00238	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	7.62e-05	0.00234	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.52e-05	0.00231	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	7.41e-05	0.00228	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	6.58e-05	0.00202	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	6.36e-05	0.00195	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	6.26e-05	0.00192	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.22e-05	0.00191	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	6e-05	0.00184	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	5.83e-05	0.00179	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	5.69e-05	0.00175	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	5.56e-05	0.00171	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	5.49e-05	0.00169	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.33e-05	0.00164	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	5.13e-05	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.08e-05	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.91e-05	0.00151	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	4.85e-05	0.000177	CcSEcCtD
Lenalidomide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	4.84e-05	0.000177	CcSEcCtD
Lenalidomide—Fatigue—Etoposide—peripheral nervous system neoplasm	4.84e-05	0.000177	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.84e-05	0.000177	CcSEcCtD
Lenalidomide—Stomatitis—Epirubicin—peripheral nervous system neoplasm	4.81e-05	0.000176	CcSEcCtD
Lenalidomide—Pain—Etoposide—peripheral nervous system neoplasm	4.8e-05	0.000175	CcSEcCtD
Lenalidomide—Constipation—Etoposide—peripheral nervous system neoplasm	4.8e-05	0.000175	CcSEcCtD
Lenalidomide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.8e-05	0.000175	CcSEcCtD
Lenalidomide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.8e-05	0.000175	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000175	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000175	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000174	CcSEcCtD
Lenalidomide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.76e-05	0.000174	CcSEcCtD
Lenalidomide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4.74e-05	0.000173	CcSEcCtD
Lenalidomide—Sweating—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.000173	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	4.73e-05	0.000173	CcSEcCtD
Lenalidomide—Haematuria—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.000172	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	4.67e-05	0.000171	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.00017	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.00017	CcSEcCtD
Lenalidomide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	4.65e-05	0.00017	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000169	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	4.63e-05	0.000169	CcSEcCtD
Lenalidomide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	4.63e-05	0.000169	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000169	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—peripheral nervous system neoplasm	4.61e-05	0.000168	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000168	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	4.59e-05	0.000168	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	4.59e-05	0.000168	CcSEcCtD
Lenalidomide—Dizziness—Vincristine—peripheral nervous system neoplasm	4.58e-05	0.000167	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	4.58e-05	0.00141	CbGpPWpGaD
Lenalidomide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	4.57e-05	0.000167	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	4.57e-05	0.000167	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—peripheral nervous system neoplasm	4.57e-05	0.000167	CcSEcCtD
Lenalidomide—Rash—Alitretinoin—peripheral nervous system neoplasm	4.53e-05	0.000166	CcSEcCtD
Lenalidomide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	4.53e-05	0.000165	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000165	CcSEcCtD
Lenalidomide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	4.52e-05	0.000165	CcSEcCtD
Lenalidomide—Bradycardia—Epirubicin—peripheral nervous system neoplasm	4.51e-05	0.000165	CcSEcCtD
Lenalidomide—Headache—Alitretinoin—peripheral nervous system neoplasm	4.51e-05	0.000164	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	4.49e-05	0.000164	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000163	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.46e-05	0.00137	CbGpPWpGaD
Lenalidomide—Urticaria—Etoposide—peripheral nervous system neoplasm	4.46e-05	0.000163	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000163	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	4.45e-05	0.000162	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	4.44e-05	0.00136	CbGpPWpGaD
Lenalidomide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	4.44e-05	0.000162	CcSEcCtD
Lenalidomide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	4.44e-05	0.000162	CcSEcCtD
Lenalidomide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	4.44e-05	0.000162	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000162	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000162	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000162	CcSEcCtD
Lenalidomide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000162	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000161	CcSEcCtD
Lenalidomide—Vomiting—Vincristine—peripheral nervous system neoplasm	4.41e-05	0.000161	CcSEcCtD
Lenalidomide—Asthenia—Cisplatin—peripheral nervous system neoplasm	4.4e-05	0.00016	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	4.4e-05	0.00016	CcSEcCtD
Lenalidomide—PTGS2—Disease—GNS—peripheral nervous system neoplasm	4.39e-05	0.00135	CbGpPWpGaD
Lenalidomide—Sweating—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.00016	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.00016	CcSEcCtD
Lenalidomide—Rash—Vincristine—peripheral nervous system neoplasm	4.37e-05	0.00016	CcSEcCtD
Lenalidomide—Dermatitis—Vincristine—peripheral nervous system neoplasm	4.37e-05	0.000159	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	4.36e-05	0.000159	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000159	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.000159	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000158	CcSEcCtD
Lenalidomide—Headache—Vincristine—peripheral nervous system neoplasm	4.34e-05	0.000158	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000158	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000157	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.28e-05	0.000156	CcSEcCtD
Lenalidomide—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.27e-05	0.000156	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.27e-05	0.000156	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	4.26e-05	0.00131	CbGpPWpGaD
Lenalidomide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000156	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.22e-05	0.0013	CbGpPWpGaD
Lenalidomide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.19e-05	0.000153	CcSEcCtD
Lenalidomide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	4.19e-05	0.000153	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	4.17e-05	0.000152	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000151	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.14e-05	0.000151	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000151	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.00015	CcSEcCtD
Lenalidomide—Nausea—Vincristine—peripheral nervous system neoplasm	4.12e-05	0.00015	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.00015	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.00015	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	4.11e-05	0.00015	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.00015	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.00015	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000149	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	4.07e-05	0.000148	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	4.05e-05	0.000148	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000147	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—peripheral nervous system neoplasm	4.03e-05	0.000147	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	4.03e-05	0.000147	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000147	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000147	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	4e-05	0.000146	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.000146	CcSEcCtD
Lenalidomide—Chills—Epirubicin—peripheral nervous system neoplasm	3.97e-05	0.000145	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—peripheral nervous system neoplasm	3.97e-05	0.000145	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.96e-05	0.000144	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.95e-05	0.000144	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000143	CcSEcCtD
Lenalidomide—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.9e-05	0.000142	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000142	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	3.88e-05	0.000141	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	3.87e-05	0.00119	CbGpPWpGaD
Lenalidomide—Rash—Cisplatin—peripheral nervous system neoplasm	3.86e-05	0.000141	CcSEcCtD
Lenalidomide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.86e-05	0.000141	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000141	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000141	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.84e-05	0.00014	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.00014	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000139	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000139	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000139	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000139	CcSEcCtD
Lenalidomide—Tension—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000138	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000138	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000137	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.74e-05	0.00115	CbGpPWpGaD
Lenalidomide—Back pain—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000136	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000136	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—peripheral nervous system neoplasm	3.71e-05	0.000136	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.000135	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000135	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.000135	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000134	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	3.67e-05	0.00113	CbGpPWpGaD
Lenalidomide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000134	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	3.65e-05	0.00112	CbGpPWpGaD
Lenalidomide—Nausea—Cisplatin—peripheral nervous system neoplasm	3.64e-05	0.000133	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000133	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000132	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.6e-05	0.00111	CbGpPWpGaD
Lenalidomide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000131	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000131	CcSEcCtD
Lenalidomide—Vomiting—Etoposide—peripheral nervous system neoplasm	3.57e-05	0.00013	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.00013	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.00013	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.00013	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000129	CcSEcCtD
Lenalidomide—Rash—Etoposide—peripheral nervous system neoplasm	3.54e-05	0.000129	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—peripheral nervous system neoplasm	3.54e-05	0.000129	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	3.52e-05	0.00108	CbGpPWpGaD
Lenalidomide—Headache—Etoposide—peripheral nervous system neoplasm	3.52e-05	0.000128	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000128	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—peripheral nervous system neoplasm	3.5e-05	0.000128	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000128	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.48e-05	0.00107	CbGpPWpGaD
Lenalidomide—Malaise—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000127	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	3.48e-05	0.00107	CbGpPWpGaD
Lenalidomide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000126	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000126	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000126	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	3.45e-05	0.000126	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000126	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000125	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.000124	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	3.39e-05	0.00104	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000124	CcSEcCtD
Lenalidomide—Cough—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000123	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000123	CcSEcCtD
Lenalidomide—Nausea—Etoposide—peripheral nervous system neoplasm	3.33e-05	0.000122	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.000122	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000121	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	3.3e-05	0.00012	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.00012	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.00012	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.00012	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.28e-05	0.00012	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.27e-05	0.000119	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000119	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.24e-05	0.000118	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000117	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000117	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000117	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.2e-05	0.000117	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000117	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000116	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.15e-05	0.000115	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.000115	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000114	CcSEcCtD
Lenalidomide—Infection—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000114	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.000114	CcSEcCtD
Lenalidomide—Shock—Epirubicin—peripheral nervous system neoplasm	3.1e-05	0.000113	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.09e-05	0.000113	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.08e-05	0.000112	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	0.000112	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.07e-05	0.000112	CcSEcCtD
Lenalidomide—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	3.07e-05	0.000942	CbGpPWpGaD
Lenalidomide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.000112	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.04e-05	0.000111	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.04e-05	0.000111	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.04e-05	0.000111	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.04e-05	0.000111	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.00011	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	3.02e-05	0.000928	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.02e-05	0.000928	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.00011	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.00011	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000109	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000108	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.94e-05	0.000107	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000107	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.91e-05	0.000106	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000106	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.87e-05	0.000105	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	0.000105	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.86e-05	0.000879	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	0.000104	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.85e-05	0.000104	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.85e-05	0.000104	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.000104	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	0.000103	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000103	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000103	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.000102	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.8e-05	0.000102	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	0.000101	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.77e-05	0.000101	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.74e-05	0.000843	CbGpPWpGaD
Lenalidomide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.74e-05	9.99e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.74e-05	0.00084	CbGpPWpGaD
Lenalidomide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.72e-05	9.93e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.72e-05	9.92e-05	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.72e-05	0.000834	CbGpPWpGaD
Lenalidomide—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.71e-05	9.9e-05	CcSEcCtD
Lenalidomide—Pain—Epirubicin—peripheral nervous system neoplasm	2.69e-05	9.82e-05	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—peripheral nervous system neoplasm	2.69e-05	9.82e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	2.66e-05	0.000816	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	9.68e-05	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.63e-05	9.61e-05	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.61e-05	9.54e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.6e-05	0.0008	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	9.48e-05	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.59e-05	9.47e-05	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.59e-05	9.45e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.57e-05	9.39e-05	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	9.36e-05	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.53e-05	9.24e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	9.18e-05	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	9.16e-05	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.5e-05	9.13e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	2.5e-05	0.000767	CbGpPWpGaD
Lenalidomide—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	9.09e-05	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	9.09e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.49e-05	9.08e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.49e-05	9.08e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.48e-05	0.000762	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.42e-05	0.000742	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	2.4e-05	0.000738	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	8.76e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.38e-05	8.69e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.32e-05	8.46e-05	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	8.44e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.3e-05	8.4e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.3e-05	8.4e-05	CcSEcCtD
Lenalidomide—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.26e-05	8.24e-05	CcSEcCtD
Lenalidomide—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.23e-05	8.13e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	2.23e-05	0.000684	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.19e-05	0.000671	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.15e-05	7.86e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	7.83e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	2.14e-05	0.000658	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	2.14e-05	0.000658	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.1e-05	0.000644	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	7.63e-05	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.08e-05	7.6e-05	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.06e-05	7.52e-05	CcSEcCtD
Lenalidomide—Vomiting—Epirubicin—peripheral nervous system neoplasm	2e-05	7.3e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.99e-05	7.27e-05	CcSEcCtD
Lenalidomide—Rash—Epirubicin—peripheral nervous system neoplasm	1.98e-05	7.24e-05	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.98e-05	7.24e-05	CcSEcCtD
Lenalidomide—Headache—Epirubicin—peripheral nervous system neoplasm	1.97e-05	7.2e-05	CcSEcCtD
Lenalidomide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	7.03e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	1.88e-05	0.000578	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—peripheral nervous system neoplasm	1.87e-05	6.82e-05	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.85e-05	6.76e-05	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—peripheral nervous system neoplasm	1.84e-05	6.7e-05	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.83e-05	6.7e-05	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	6.66e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.79e-05	0.000551	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	1.77e-05	0.000543	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.76e-05	0.00054	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.73e-05	6.31e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.58e-05	0.000485	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.49e-05	0.000456	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	1.44e-05	0.000443	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.42e-05	0.000435	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.33e-05	0.00041	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.27e-05	0.000391	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.25e-05	0.000385	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	1.2e-05	0.000368	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	1.02e-05	0.000314	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	9.47e-06	0.000291	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	7.2e-06	0.000221	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—peripheral nervous system neoplasm	6.71e-06	0.000206	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	5.27e-06	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	4.65e-06	0.000143	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	3.9e-06	0.00012	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.76e-06	8.48e-05	CbGpPWpGaD
